Become a Readings Member to make your shopping experience even easier. Sign in or sign up for free!

Become a Readings Member. Sign in or sign up for free!

Hello Readings Member! Go to the member centre to view your orders, change your details, or view your lists, or sign out.

Hello Readings Member! Go to the member centre or sign out.

Molecular Therapy of Breast Cancer: Classicism Meets Modernity
Hardback

Molecular Therapy of Breast Cancer: Classicism Meets Modernity

$355.99
Sign in or become a Readings Member to add this title to your wishlist.

Breast cancer is the most frequently diagnosed type of cancer and a second leading cause of cancer death in women after lung cancer. Despite their proven efficacy, classical therapies are, however, unable to cure metastatic breast cancer and are often associated with significant toxicity and side-effects, due to a wide spectrum of action. During the last years, our increasing knowledge of the molecular pathways underlying cancer development has led to the introduction of new drugs, of which most are directed towards very specific targets. Rather than to be used as single agents, these modern compounds could ultimately be combined with classical molecules. Here are described nearly 150 drugs that are currently used in routine therapy or are in clinical trials in breast cancer patients. From the classical tamoxifen, fluorouracil, cyclophosphamide, doxorubicin, epirubin, docetaxel, paclitaxel…, to the more recently introduced ixabepilone, lapatinib, vorinostat, everolimus, bevacizumab…, they also include capecitabine, gemcitabine, trastuzumab, bevacizumab, fulvestrant, aromatase inhibitors, cancer vaccines, inhibitors of tumour-induced osteolysis, insulin-like growth factor-I receptor inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors, and many others. This book offers an insight into current developments of breast cancer therapy, when classicism meets modernity.

Read More
In Shop
Out of stock
Shipping & Delivery

$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout

MORE INFO
Format
Hardback
Publisher
Nova Science Publishers Inc
Country
United States
Date
1 July 2009
Pages
291
ISBN
9781607415930

Breast cancer is the most frequently diagnosed type of cancer and a second leading cause of cancer death in women after lung cancer. Despite their proven efficacy, classical therapies are, however, unable to cure metastatic breast cancer and are often associated with significant toxicity and side-effects, due to a wide spectrum of action. During the last years, our increasing knowledge of the molecular pathways underlying cancer development has led to the introduction of new drugs, of which most are directed towards very specific targets. Rather than to be used as single agents, these modern compounds could ultimately be combined with classical molecules. Here are described nearly 150 drugs that are currently used in routine therapy or are in clinical trials in breast cancer patients. From the classical tamoxifen, fluorouracil, cyclophosphamide, doxorubicin, epirubin, docetaxel, paclitaxel…, to the more recently introduced ixabepilone, lapatinib, vorinostat, everolimus, bevacizumab…, they also include capecitabine, gemcitabine, trastuzumab, bevacizumab, fulvestrant, aromatase inhibitors, cancer vaccines, inhibitors of tumour-induced osteolysis, insulin-like growth factor-I receptor inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors, and many others. This book offers an insight into current developments of breast cancer therapy, when classicism meets modernity.

Read More
Format
Hardback
Publisher
Nova Science Publishers Inc
Country
United States
Date
1 July 2009
Pages
291
ISBN
9781607415930